Tirzepatide is an advanced dual incretin receptor agonist designed to engage both GIP and GLP-1 pathways simultaneously, representing a significant evolution in metabolic peptide research. This dual-mechanism approach has generated strong scientific interest due to its potential influence on insulin signaling and nutrient-partitioning pathways. Ongoing studies continue to evaluate its role in metabolic regulation models and energy utilization frameworks. Researchers are particularly interested in how multi-receptor targeting may enhance pathway efficiency compared to single-receptor compounds. As next-generation metabolic peptides emerge, Tirzepatide stands at the forefront of investigational endocrinology research.